NASDAQ:XCUR Exicure (XCUR) Stock Price, News & Analysis $11.19 +5.37 (+92.27%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends About Exicure Stock (NASDAQ:XCUR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Exicure alerts:Sign Up Key Stats Today's Range$6.83▼$14.8050-Day Range$1.53▼$11.1952-Week Range$1.44▼$14.80Volume22.86 million shsAverage Volume583,256 shsMarket Capitalization$24.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewExicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.Read More… Top "Sleeping Giant" Crypto In The Market Now (Ad)Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future. Click here to discover our #1 crypto pick before it's too late Exicure Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks36th Percentile Overall ScoreXCUR MarketRank™: Exicure scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Exicure. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Exicure is -5.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exicure is -5.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExicure has a P/B Ratio of 15.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Exicure's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.71% of the float of Exicure has been sold short.Short Interest Ratio / Days to CoverExicure has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Exicure has recently increased by 72.78%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldExicure does not currently pay a dividend.Dividend GrowthExicure does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.67 Percentage of Shares Shorted4.71% of the float of Exicure has been sold short.Short Interest Ratio / Days to CoverExicure has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Exicure has recently increased by 72.78%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News SentimentN/A News SentimentExicure has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Exicure this week, compared to 0 articles on an average week.Search Interest7 people have searched for XCUR on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Exicure insiders have bought more of their company's stock than they have sold. Specifically, they have bought $711,669.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.40% of the stock of Exicure is held by insiders.Percentage Held by Institutions42.82% of the stock of Exicure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exicure's insider trading history. Receive XCUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exicure and its competitors with MarketBeat's FREE daily newsletter. Email Address XCUR Stock News HeadlinesExicure Signs Equity-Financing Deals With HiTron SystemsNovember 14, 2024 | marketwatch.comXCUR/USD - Curate US DollarOctober 28, 2024 | investing.com[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.November 21, 2024 | Crypto Swap Profits (Ad)(PNGJL.BO)September 19, 2024 | finance.yahoo.comExicure Shares More Than Double After Nasdaq Listing ExtensionSeptember 18, 2024 | marketwatch.comExicure, Inc. Receives Extension from Nasdaq Hearings PanelSeptember 18, 2024 | finance.yahoo.comExicure, Inc. Receives Extension from Nasdaq Hearings PanelSeptember 18, 2024 | businesswire.comWhat's Going On With Exicure Shares Monday?September 16, 2024 | msn.comSee More Headlines XCUR Stock Analysis - Frequently Asked Questions How have XCUR shares performed this year? Exicure's stock was trading at $0.5803 at the beginning of the year. Since then, XCUR stock has increased by 1,828.3% and is now trading at $11.19. View the best growth stocks for 2024 here. How were Exicure's earnings last quarter? Exicure, Inc. (NASDAQ:XCUR) announced its quarterly earnings results on Friday, November, 19th. The company reported ($40.50) earnings per share for the quarter, missing the consensus estimate of ($13.50) by $27.00. The business had revenue of ($3.68) million for the quarter, compared to the consensus estimate of $0.80 million. When did Exicure's stock split? Exicure's stock reverse split on Tuesday, August 27th 2024. The 1-5 reverse split was announced on Monday, August 26th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. Who are Exicure's major shareholders? Top institutional investors of Exicure include Carlyle Group Inc. (3.26%) and Northwestern University (0.60%). Insiders that own company stock include Co Ltd Dgp, Cbi Usa, Inc and Gates Frontier, Llc. View institutional ownership trends. How do I buy shares of Exicure? Shares of XCUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Exicure own? Based on aggregate information from My MarketBeat watchlists, some other companies that Exicure investors own include Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Tesla (TSLA), Meta Platforms (META), NIO (NIO), Viking Therapeutics (VKTX) and Energy Transfer (ET). Company Calendar Last Earnings11/19/2021Today11/20/2024Fiscal Year End12/31/2024Next Earnings (Estimated)5/15/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XCUR CUSIPN/A CIK1698530 Webwww.exicuretx.com Phone(847) 673-1700FaxN/AEmployees50Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,910,000.00 Net MarginsN/A Pretax Margin-799.80% Return on Equity-190.90% Return on Assets-36.75% Debt Debt-to-Equity RatioN/A Current Ratio0.71 Quick Ratio0.61 Sales & Book Value Annual Sales$28.83 million Price / Sales0.84 Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book15.76Miscellaneous Outstanding Shares2,170,000Free Float1,990,000Market Cap$24.28 million OptionableNot Optionable Beta1.28 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:XCUR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exicure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.